Pegcetacoplan (paroxysmal nocturnal hemoglubinuria (PNH), pre-treated patients)

Subject:

• Active Substance: Pegcetacoplan
• Name: Aspaveli^®
• Therapeutic area: Paroxysmal nocturnal hemoglubinuria (PNH)
• Pharmaceutical company: Swedish Orphan Biovitrum GmbH

Time table:

• Start: 01.04.2022
• Final decision by G-BA: 15.09.2022

Final decision:

• Hint for a non-quantifiable additional benefit